VPPRN Patient-Powered Research
Behçet's Disease (BD)
Every 6 months, we ask our VPPRN community to check-in and tell us how they are doing. The graphs below reflect the scores/ratings of patients with Behçet’s Disease (BD) compared to the Network as a whole. Here is what we learned about flares, fatigue, pain, symptoms of vasculitis, and members’ current state of vasculitis at the January 2026 check-in:
- Compared to patients with other forms of vasculitis, patients with BD reported the following:
- more flares
- higher scores for fatigue
- higher scores for their symptoms of vasculitis over the past 28 days
- higher scores for pain
- a larger percentage of patients with BD reported their vasculitis as active.
- Compared to patients with other forms of vasculitis, patients with BD reported the following:
If you have concerns about your health scores, please discuss with your rheumatologist or primary care provider.
- Not a member? Click JOIN THE VPPRN button below.
- Already a VPPRN Member? Use the LOGIN button to access your account.
FLARES and VASCULITIS
Flare Reporting: At the January 2026 check-in, patients with BD reported more flares in the past 6 months (70%) compared to 21% in the VPPRN community. This is a trend we have seen consistently for the past 6 VPPRN check-ins from January 2023-January 2026.
FATIGUE and VASCULITIS
Fatigue: Patients with BD reported higher fatigue levels on average in the past 7 days than the overall VPPRN community. In January 2026, 53% reported fatigue “quite a bit” or “very much” compared with 31% of all VPPRN participants.
PAIN and VASCULITIS
Pain: Patients with BD reported higher levels of pain than the overall VPPRN community. At the January 2026 check-in, only 15% of patients with BD reported no pain (score of 0), compared with 28% of participants across the VPPRN community.
MEMBERS' CURRENT STATE OF VASCULITIS
Members’ Current State of Vasculitis: Patients with BD were more likely to report active vasculitis than the overall VPPRN community. At the January 2026 check-in, 68% of patients with BD reported active disease, compared with 21% of participants across the Network.